Skip to Content

B.1.1.7 SARS-CoV-2 Variant More Transmissible but Not Linked to More Severe Illness, Death

WEDNESDAY, April 14, 2021 -- The B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not associated with more severe illness or death but leads to higher viral load and is associated with increased R1, according to two studies published online April 12 in The Lancet Infectious Diseases and The Lancet Public Health.

Dan Frampton, Ph.D., from University College London, and colleagues sequenced and analyzed samples from hospitalized patients for the presence of the B.1.1.7 variant of concern. The researchers found that 58 percent of the 341 patients with samples that could be sequenced had B.1.1.7 infection. In unadjusted and adjusted analyses, there was no evidence of a correlation between severe disease and death and lineage. Viral load by proxy was higher in B.1.1.7 samples than in non-B.1.1.7 samples.

Mark S. Graham, Ph.D., from King's College London, and colleagues examined the association between the SARS-CoV-2 B.1.1.7 variant and reported symptoms, disease course, rates of reinfection, and transmissibility among users of the COVID Symptom Study app with a positive COVID-19 test between Sept. 28 and Dec. 27, 2020, when the prevalence of B.1.1.7 increased. The researchers observed no change in reported symptoms or disease duration associated with B.1.1.7. Possible reinfections were identified during this time for 0.7 percent of 36,509 app users who reported a positive test before Oct. 1, 2020, with no evidence for increased frequency of reinfection with the B.1.1.7 variant. Relative to preexisting variants, there was a multiplicative increase in the R1 of B.1.1.7 by a factor of 1.35.

"This study adds to the consensus that B.1.1.7 has increased transmissibility, which has contributed in large part to the sharp rise in cases in the U.K. over the study period and beyond," write the authors of an accompanying editorial.

One author from the Frampton study disclosed financial ties to the pharmaceutical and medical device industries. Several authors from the Graham study disclosed ties to Zoe Global, which partially funded the study.

Abstract/Full Text - Frampton

Editorial

Abstract/Full Text - Graham

Editorial

© 2021 HealthDay. All rights reserved.

Read this next

Physician's Briefing Weekly Coronavirus Roundup

Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of May 3 to 7, 2021. This roundup...

Poll Finds Many Parents Hesitant to Get Younger Children Vaccinated

FRIDAY, May 7, 2021 -- As U.S. health officials prepare to authorize the Pfizer COVID-19 vaccine for emergency use in younger children, a new poll shows that less than a third of...

U.S. Likely to Achieve July 4 COVID-19 Vaccination Target, but Challenges Remain

FRIDAY, May 7, 2021 -- It is likely that the United States will achieve President Joe Biden's target of having at least one dose of a COVID-19 vaccine into the arms of 70 percent...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.